Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Drug Delivery

OINDPs: Nosey about recent developments?

OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Analysis

Beckman introduces novel CE-Marked Hepatitis Assays at ESCMID Global

The HBsAg high positive algorithm eliminates the need for repeat and confirmatory testing for samples ≥ 100.00 S/CO
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Transforming healthcare with patient centricity

In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
Manufacturing

Medincell collaborates with AbbVie to develop next-generation long-acting injectable therapies

The partnership will focus on the development and commercialisation of six long-acting injectable therapies across various therapeutic areas
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Subscribe now